Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
Peter R. Galle, Richard S. Finn, Shukui Qin, Masafumi Ikeda, Andrew X. Zhu, Tae‐You Kim, Masatoshi Kudo, В. В. Бредер, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Sohail Mulla, Wendy Verret, Derek-Zhen Xu, Sairy Hernandez, Beiying Ding, Juan Liu, Chen Huang, Ho Yeong Lim, Ann‐Lii Cheng, Michel Ducreux
Topics & Concepts
MedicineSorafenibBevacizumabAtezolizumabInternal medicineOncologyHepatocellular carcinomaQuality of life (healthcare)Response Evaluation Criteria in Solid TumorsClinical trialProgression-free survivalPerformance statusCancerClinical endpointPhases of clinical researchSurgeryChemotherapyPembrolizumabImmunotherapyNursingHepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies